Search

Your search keyword '"Hartog, Nicholas L."' showing total 15 results
Start Over Author "Hartog, Nicholas L." Database Supplemental Index
15 results on '"Hartog, Nicholas L."'

1. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology.

Author

Lieberman, Jay A., Chu, Derek K., Ahmed, Tasnuva, Dribin, Timothy E., Abrams, Elissa M., Anagnostou, Aikaterini, Blumenthal, Kimberly G., Boguniewicz, Mark, Chase, Nicole M., Golden, David B.K., Hartog, Nicholas L., Heimall, Jennifer R., Ho, Tina, Lawrence, Monica G., Khan, David A., Minniear, Timothy Dean, Mustafa, S. Shahzad, Oppenheimer, John J., Phillips, Elizabeth J., and Ramsey, Allison

Published
2024
Full Text
View/download PDF

2. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology

Author

Lieberman, Jay A., Chu, Derek K., Ahmed, Tasnuva, Dribin, Timothy E., Abrams, Elissa M., Anagnostou, Aikaterini, Blumenthal, Kimberly G., Boguniewicz, Mark, Chase, Nicole M., Golden, David B.K., Hartog, Nicholas L., Heimall, Jennifer R., Ho, Tina, Lawrence, Monica G., Khan, David A., Minniear, Timothy Dean, Mustafa, S. Shahzad, Oppenheimer, John J., Phillips, Elizabeth J., Ramsey, Allison, Rider, Nicholas L., Schneider, Lynda, Shaker, Marcus S., Spergel, Jonathan M., Stone, Cosby A., Stukus, David R., Wang, Julie, and Greenhawt, Matthew J.

Abstract

Dupilumab is a monoclonal antibody that targets the interleukin (IL)-4 receptor alpha subunit, thus blocking the effects of IL-4 and IL-13, and has shown efficacy in treating various conditions including asthma, atopic dermatitis, eosinophilic esophagitis, and others. Because of its immune modulatory effects, clinical trials that studied dupilumab did not allow patients to receive live vaccines during the clinical trials because of an abundance of caution, and thus package inserts recommend that patients who are being treated with dupilumab should avoid live vaccines. Because dupilumab is now approved for use in patients from 6 months of age for the treatment of atopic dermatitis, this reported contraindication is now posing a clinical dilemma for patients and clinicians.

Published
2024
Full Text
View/download PDF

3. WD Repeat Domain 1 (WDR1) Deficiency Presenting as a Cause of Infantile Inflammatory Bowel Disease

Author

Millstead, Jenna, Kamat, Aarti, Duffner, Ulrich, Abdel-Mageed, Aly, Freswick, Peter, Dickens, David, Stumph, Jennifer, Prokop, Jeremy W., and Hartog, Nicholas L.

Abstract

Infantile and very early onset inflammatory bowel disease (VEOIBD) are a rare phenomenon wherein patients develop intestinal inflammation with typical IBD symptoms before ages 2 and 6, respectively. In recent years, there has been an increasing number of monogenetic immunological disorders identified that lead a child to develop VEOIBD. We present a case of an infant boy who presented with hematochezia and thrombocytopenia in the first week of life and developed IBD by the age of 1 month. Additional clues to his diagnosis included lymphopenia and nuclear herniation observed in his neutrophils. Compound heterozygous damaging variants were identified in WD Repeat Domain 1 (WDR1) by whole-exome sequencing (WES) and represents a novel cause of VEOIBD. Our patient's IBD and immunologic phenotype was successfully treated by hematopoietic stem cell transplant (HSCT).

Published
2020
Full Text
View/download PDF

5. Corrigendum to <‘A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology’> <[Annals of Allergy, Asthma & Immunology 133 (2024) 286-94]>

Author

Lieberman, Jay A., Chu, Derek K., Ahmed, Tasnuva, Dribin, Timothy E., Abrams, Elissa M., Anagnostou, Aikaterini, Blumenthal, Kimberly G., Boguniewicz, Mark, Chase, Nicole M., Golden, David B.K., Hartog, Nicholas L., Heimall, Jennifer R., Ho, Tina, Lawrence, Monica G., Khan, David A., Minniear, Timothy Dean, Mustafa, S. Shahzad, Oppenheimer, John J., Phillips, Elizabeth J., Ramsey, Allison, Rider, Nicholas L., Schneider, Lynda, Shaker, Marcus S., Spergel, Jonathan M., Stone, Cosby A., Stukus, David R., Wang, Julie, and Greenhawt, Matthew J.

Published
2024
Full Text
View/download PDF

7. Rat Bite Fever

Author

Hartog, Nicholas L. and Wiblin, Raymond Todd

Abstract

Rat bite fever is a rare zoonotic infection caused by the pleomorphic gram-negative rod, Streptobacillus moniliformis. Schottmuler first identified S moniliformisas the causative organism of rat bite fever in 1914. Although a bite is not required to contract rat bite fever, it seems that the risk of infection after a rat bite is approximately 10. In fact, 34 of the reported cases did not report a known bite. The disease is typically characterized by vague symptoms such as fever, rigors, maculopapular to petechial rash, migratory polyarthralgias, headache, nauseavomiting, sore throat, and severe myalgias. Detailed social history and exposure to rats are key to the diagnosis. Untreated, rat bite fever can carry a mortality rate of 10. Patients with endocarditis carry a 53 mortality rate. Other known complications of rat bite fever include myocarditis, pericarditis, systemic vasculitis, polyarteritis nodosa, meningitis, hepatitis, nephritis, pneumonia, and focal abscesses.

Published
2014
Full Text
View/download PDF

9. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure

Author

Murphy, Kevin R., Chipps, Bradley, Beuther, David A., Wise, Robert A., McCann, William, Gilbert, Ileen, Eudicone, James M., Gandhi, Hitesh N., Harding, Gale, Coyne, Karin S., Zeiger, Robert S., Kobernick, Aaron K., Mohammad, Acklema, Cherry, Adam T., Fein, Alan, Gaines, Alan, Ramsey, Allison, Michaud, Amanda L., Palmer, Amy, Kim, Andrew S., Smith, Andrew M., White, Andrew A., Ricci, Anthony R., Kettelhut, Brett V., Modena, Brian D., Stone, Brian, Rolston, B. Steele, Schnapf, Bruce M., Krajicek, Bryan, Kraft, Cara, Hopkins, Carly, Natalie, Chitra R., Anderson, Christine, Czajkowski, Christine, Arce, Daisy, Hamlin, Danuel, Hill, David G., Mares, David C., Pham, David, Liao, Da-Wei, Simmons, Deborah, Johnson, Derek K., Jhaveri, Devi K., Maselli, Diego J., Kerwin, Edward, Schuman, Edward, Sher, Ellen R., Bleecker, Eugene, Rakowski, Ewa, Ida Hsu, Florence, Averill, Francis J., Barsanti, Franco, Gross, Gary N., Chupp, Geoffrey Lowell, Head, G. Gilbert, Nasir, Hassan, Lee, Howard J., Barjaktarevic, Igor, Cook, J. Paul, Krainson, James P., Pearl, James E., Bellak, Jason M., Perez-Fernandez, Javier, Rehm, Jeffrey, Trevor, Jennifer, Freyer Most, Jessica, Hanson, Jill, Blessing-Moore, Joann, Biller, Jodi H., Gedell, John, Southard, John G., Chancellor, Jon Eric, Ilowite, Jonathan, Romeo, Jonathan R., Manuel Mercado, Jorge, Dominic Fisher, Joseph, Greiwe, Justin, Gregory, Karen L., Nadeau, Kari, Shenoy, Kartik V., Tan, Laren D., Stefanowicz, Leslie A., Humes, Lindsay D., Bowers, Lori A., Edel O’Connor, Maeve, Perez, Mario F., White, Martha V., Hegewald, Matthew, Wilson, Matthew C., Sikora, Maxcie M., Lee Morganroth, Melvin, Smith, Mitchell, Farooqui, Nabeel, James Lesch, Nathan, Jain, Neal, Parikh, Neil, Hartog, Nicholas L., Luthin, Patricia L., Stewart, Patricia H., Rubio O’Connor, Peggy, Schochet, Peter, Goldberg, Pinkus, Patel, Pulin P., Chinthrajah, R. Sharon, Sidhu, Rabinder, Ayinla, Raji M., Brown, Randall, Stadtler, Reneé, Wachs, Richard A., Balkissoon, Ronald C., Duplantier, Rory L., Puente, Rosalba E., Settipane, Russell, Mustafa, S. Shahzad, Surani, Salim, Abdul Jawad, Sami, Adams, Sandra G., Villegas, Sarah, Al-Farra, Sherif, Subramanian, Shyamsunder, Bains, Sonia N., Kelsen, Steven G., Wise, Steven L., Estrella-Eades, Susan, Smith, Susan M., Qureshi, Tabarak, Chen, Taiwen, Kelbel, Theodore E., Miller, Thomas P., Jain, Vipin, Soong, Weily, Soler, Xavier, and Mattar, Ziad R.

Abstract

Asthma exacerbation risk increases with worsening asthma control. Prevailing numerical control tools evaluate only current symptom impairment despite the importance of also assessing risk based on exacerbation history. An easy-to-use questionnaire addressing impairment and risk domains of control is needed.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results